[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report
Wiener klinische Wochenschrift · 2025
DOI: 10.1007/s00508-025-02642-3 ↗Kurz gefasst
Fallbericht in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Ilva Kristiana Langrate und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antigens, Surface, Bone Neoplasms, Glutamate Carboxypeptidase II, Lutetium. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
The [ 177 Lu]Lu-PSMA radioligand therapy is a prostate-specific membrane antigen (PSMA) targeting treatment approved for patients with metastatic castration-resistant prostate cancer, after failure of androgen deprivation therapy or taxane-based chemotherapy. We report a unique case of a patient with metastatic hormone-sensitive prostate cancer (mHSPC) who received PSMA radioligand therapy as the sole treatment, without any prior or additional systemic treatment. Over a span of 8 years, the patient underwent 12 cycles of [ 177 Lu]Lu-PSMA radioligand therapy, demonstrating favorable therapeutic response and a prolonged androgen deprivation therapy-free period. This case highlights the potential of long-term PSMA radioligand therapy as a standalone option in selected mHSPC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA.
- Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan.
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Urology, Weill Cornell Medical College, New York, USA.
Förderung
- Medical University of Vienna
Zitieren
APA
Langrate, I. K., Kretschmer-Chott, E., Schmitl, S., Shariat, S. F., Hacker, M., Kramer, G., & Rasul, S. (2025). [177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-025-02642-3
Vancouver
Langrate IK, Kretschmer-Chott E, Schmitl S, Shariat SF, Hacker M, Kramer G, et al. [177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-025-02642-3
BibTeX
@article{Langrate2025,
author = {Langrate, Ilva Kristiana and Kretschmer-Chott, Elisabeth and Schmitl, Stefan and Shariat, Shahrokh F and Hacker, Marcus and Kramer, Gero and Rasul, Sazan},
title = {[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report},
journal = {Wiener klinische Wochenschrift},
year = {2025},
doi = {10.1007/s00508-025-02642-3}
}
EUVIMED